$DVAX
DYNAVAX TECHNOLOGIES CORP

2016 Q4 Form 10-Q Financial Statement

#000156459016027955 Filed on November 07, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2015 Q3
Revenue $7.292M $1.188M
YoY Change 964.53% -46.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.450M $5.290M
YoY Change 19.58% 25.65%
% of Gross Profit
Research & Development $18.44M $24.11M
YoY Change -11.9% -14.13%
% of Gross Profit
Depreciation & Amortization $690.0K $330.0K
YoY Change 68.29% -2.94%
% of Gross Profit
Operating Expenses $25.89M $29.63M
YoY Change -4.68% -8.23%
Operating Profit
YoY Change
Interest Expense $140.0K $62.00K
YoY Change 7.69% 55.0%
% of Operating Profit
Other Income/Expense, Net -$2.560M $17.00K
YoY Change 6300.0% -92.13%
Pretax Income -$21.74M -$30.12M
YoY Change -19.06% 1.01%
Income Tax
% Of Pretax Income
Net Earnings -$21.74M -$30.12M
YoY Change -19.06% 1.02%
Net Earnings / Revenue -298.15% -2535.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$563.9K -$824.5K
COMMON SHARES
Basic Shares Outstanding 38.53M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $81.40M $220.7M
YoY Change -58.5% 68.99%
Cash & Equivalents $24.29M $103.0M
Short-Term Investments $57.10M $117.7M
Other Short-Term Assets $6.800M $2.500M
YoY Change 183.33% -30.56%
Inventory
Prepaid Expenses
Receivables $1.300M $1.200M
Other Receivables $0.00 $0.00
Total Short-Term Assets $89.60M $224.3M
YoY Change -55.19% 66.27%
LONG-TERM ASSETS
Property, Plant & Equipment $17.17M $11.60M
YoY Change 24.41% 43.21%
Goodwill $1.971M
YoY Change -3.52%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $334.0K $800.0K
YoY Change 44.59% -46.67%
Total Long-Term Assets $20.08M $14.60M
YoY Change 20.34% 21.67%
TOTAL ASSETS
Total Short-Term Assets $89.60M $224.3M
Total Long-Term Assets $20.08M $14.60M
Total Assets $109.7M $238.9M
YoY Change -49.37% 62.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.796M $2.400M
YoY Change 10.57% -52.0%
Accrued Expenses $11.19M $13.80M
YoY Change -27.03% 13.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.00M $19.70M
YoY Change -30.56% -13.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $443.0K $8.000M
YoY Change -44.63% 220.0%
Total Long-Term Liabilities $443.0K $8.000M
YoY Change -44.63% 220.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.00M $19.70M
Total Long-Term Liabilities $443.0K $8.000M
Total Liabilities $20.48M $27.70M
YoY Change -30.81% 9.49%
SHAREHOLDERS EQUITY
Retained Earnings -$812.2M
YoY Change 16.07%
Common Stock $905.0M $886.6M
YoY Change 1.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $89.20M $211.2M
YoY Change
Total Liabilities & Shareholders Equity $109.7M $238.9M
YoY Change -49.37% 62.63%

Cashflow Statement

Concept 2016 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$21.74M -$30.12M
YoY Change -19.06% 1.02%
Depreciation, Depletion And Amortization $690.0K $330.0K
YoY Change 68.29% -2.94%
Cash From Operating Activities -$26.28M -$23.00M
YoY Change 20.27% -0.39%
INVESTING ACTIVITIES
Capital Expenditures -$1.240M -$2.580M
YoY Change -54.41% 789.66%
Acquisitions
YoY Change
Other Investing Activities $29.37M -$60.93M
YoY Change -186.82% -333.0%
Cash From Investing Activities $28.12M -$63.50M
YoY Change -176.91% -345.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -220.0K 153.0M
YoY Change -173.33% 254916.67%
NET CHANGE
Cash From Operating Activities -26.28M -23.00M
Cash From Investing Activities 28.12M -63.50M
Cash From Financing Activities -220.0K 153.0M
Net Change In Cash 1.620M 66.51M
YoY Change -102.79% 2241.9%
FREE CASH FLOW
Cash From Operating Activities -$26.28M -$23.00M
Capital Expenditures -$1.240M -$2.580M
Free Cash Flow -$25.04M -$20.42M
YoY Change 30.89% -10.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
151313000
CY2015Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1394000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44812000
CY2015Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
7361000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38527660
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2427000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
199946000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13804000
CY2015Q4 us-gaap Goodwill
Goodwill
2043000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
609000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
231000
CY2015Q4 us-gaap Assets
Assets
216633000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3433000
CY2016Q3 us-gaap Revenues
Revenues
162000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11766000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
35000000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
29629000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24105000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5524000
us-gaap Interest Expense
InterestExpense
572000
CY2015Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1671000
dvax Cash Settled Portion Of Stock Based Compensation Expense
CashSettledPortionOfStockBasedCompensationExpense
602000
us-gaap Share Based Compensation
ShareBasedCompensation
10030000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
896000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-804000
dvax Increase Decrease In Restricted Cash And Other Assets For Operating Activities
IncreaseDecreaseInRestrictedCashAndOtherAssetsForOperatingActivities
99000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
237000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
222000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
291000
dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
171000
us-gaap Repayments Of Debt
RepaymentsOfDebt
10990000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
173659000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-182000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
53520000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103031000
us-gaap Interest Paid
InterestPaid
720000
dvax Accrual For Litigation Settlement And Insurance Recovery
AccrualForLitigationSettlementAndInsuranceRecovery
4050000
us-gaap Loss Contingency Settlement Agreement Date
LossContingencySettlementAgreementDate
September 7, 2016
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2891000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from these estimates.</p></div>
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
196113000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
78000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
66000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
109551000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
196125000
CY2016Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
86511000
CY2016Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2016Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
86511000
CY2016Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
86530000
CY2016Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2016Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
86530000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4680000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2990000
us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
0
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
109532000
CY2016Q3 us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1351000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
109600000
CY2016Q3 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4136000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4098000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1755000
CY2015Q4 dvax Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedWeightedAveragePrice
23.34
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.95
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
13.81
CY2016Q3 dvax Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedWeightedAveragePrice
22.06
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
22.10
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
25.70
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y8M27D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
182000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
182000
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
182000
CY2015Q3 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3661000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2630000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10030000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6502000

Files In Submission

Name View Source Status
0001564590-16-027955-index-headers.html Edgar Link pending
0001564590-16-027955-index.html Edgar Link pending
0001564590-16-027955.txt Edgar Link pending
0001564590-16-027955-xbrl.zip Edgar Link pending
dvax-10q_20160930.htm Edgar Link pending
dvax-20160930.xml Edgar Link completed
dvax-20160930.xsd Edgar Link pending
dvax-20160930_cal.xml Edgar Link unprocessable
dvax-20160930_def.xml Edgar Link unprocessable
dvax-20160930_lab.xml Edgar Link unprocessable
dvax-20160930_pre.xml Edgar Link unprocessable
dvax-ex311_14.htm Edgar Link pending
dvax-ex312_15.htm Edgar Link pending
dvax-ex321_13.htm Edgar Link pending
dvax-ex322_12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending